alleged that Takeda entered into a "pay-for-delay" agreement in 2014 – a common tactic used by brand-name drug manufacturers to block generic entry, whereby the brand-name manufacturer pays a generic
In the ongoing dispute over its highly successful weight-loss drug semaglutide, Novo Nordisk has suffered a further setback as the EPO revoked yet another patent from several under attack. After the
total 1 pages, 2 items